About
KOMO Biosciences develops a non-viral precision genome engineering platform using proprietary hyperactive integrases for targeted insertion of large DNA payloads into various cell types, enabling applications in therapeutics, bioprocessing, agriculture, and industrial biotechnology.
Explore KOMO Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.